AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...

Researchers are using a groundbreaking technique to visualize a crucial molecule involved in neurotransmission in patients ...

Most cases of dementia are caused by a mixture of risk factors. A risk factor is something that affects our chances of developing a condition like dementia. For most of us our risk of dementia is made ...

Researchers from the International Working Group recommend categorizing biomarker-positive, cognitively normal individuals as ...